Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9955)
All Articles published online
|
Publishing Process of This Article
|
Mar 21, 2014 (publication date) through Apr 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20(11): 2902-2912 [PMID: 24659881 DOI: 10.3748/wjg.v20.i11.2902] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i11/2902.htm |
| Number | Citing Articles |
| 1 |
Wael Abdel-Razek, Imam Waked. Optimal Management of HCV Genotype 4. Current Hepatology Reports 2014; 13(4): 286 doi: 10.1007/s11901-014-0243-5
|
| 2 |
Celia Perales, Ana M. Ortega-Prieto, Nathan M. Beach, Julie Sheldon, Luis Menéndez-Arias, Esteban Domingo. Handbook of Antimicrobial Resistance. 2017; : 123 doi: 10.1007/978-1-4939-0694-9_1
|
| 3 |
Lize Cuypers, Francesca Ceccherini‐Silberstein, Kristel Van Laethem, Guangdi Li, Anne‐Mieke Vandamme, Jürgen Kurt Rockstroh. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Reviews in Medical Virology 2016; 26(6): 408 doi: 10.1002/rmv.1895
|
| 4 |
Zahra Hasanshahi, Ava Hashempour, Farzane Ghasabi, Javad Moayedi, Zahra Musavi, Behzad Dehghani, Heidar Sharafi, Hassan Joulaei. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01988-y
|
| 5 |
Mohsan Saeed, Eva Billerbeck, Charles M. Rice. HCV: The Journey from Discovery to a Cure. Topics in Medicinal Chemistry 2019; 31: 29 doi: 10.1007/7355_2018_51
|
| 6 |
Makonen Belema, Nicholas A. Meanwell. Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect. Journal of Medicinal Chemistry 2014; 57(12): 5057 doi: 10.1021/jm500335h
|
| 7 |
Ming-Zhi Zhang, Qiong Chen, Guang-Fu Yang. A review on recent developments of indole-containing antiviral agents. European Journal of Medicinal Chemistry 2015; 89: 421 doi: 10.1016/j.ejmech.2014.10.065
|
| 8 |
Jun Itakura, Masayuki Kurosaki, Mayu Higuchi, Hitomi Takada, Natsuko Nakakuki, Yoshie Itakura, Nobuharu Tamaki, Yutaka Yasui, Shoko Suzuki, Kaoru Tsuchiya, Hiroyuki Nakanishi, Yuka Takahashi, Shinya Maekawa, Nobuyuki Enomoto, Namiki Izumi, Naoya Sakamoto. Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. PLOS ONE 2015; 10(9): e0138060 doi: 10.1371/journal.pone.0138060
|
| 9 |
P. Trémeaux, A. Caporossi, C. Ramière, E. Santoni, N. Tarbouriech, M.-A. Thélu, K. Fusillier, L. Geneletti, O. François, V. Leroy, W.P. Burmeister, P. André, P. Morand, S. Larrat. Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains. Clinical Microbiology and Infection 2016; 22(5): 460.e1 doi: 10.1016/j.cmi.2016.01.015
|
| 10 |
Paul Y Kwo, Maaz B. Badshah. Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. Current Gastroenterology Reports 2015; 17(10) doi: 10.1007/s11894-015-0462-0
|
| 11 |
Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi, Chen-Hua Liu. Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLOS ONE 2016; 11(10): e0165339 doi: 10.1371/journal.pone.0165339
|
| 12 |
Shaihana Abdulrahman Almatrrouk, Anthony W Oliver, Lynne Hampson, Ian N Hampson. Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis. Future Virology 2014; 9(7): 679 doi: 10.2217/fvl.14.50
|
| 13 |
Dolly A. Parasrampuria. Viral Proteases and Their Inhibitors. 2017; : 469 doi: 10.1016/B978-0-12-809712-0.00014-9
|
| 14 |
Teresa I. Ng, Preethi Krishnan, Tami Pilot-Matias, Warren Kati, Gretja Schnell, Jill Beyer, Thomas Reisch, Liangjun Lu, Tatyana Dekhtyar, Michelle Irvin, Rakesh Tripathi, Clarence Maring, John T. Randolph, Rolf Wagner, Christine Collins.
In Vitro
Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
. Antimicrobial Agents and Chemotherapy 2017; 61(5) doi: 10.1128/AAC.02558-16
|
| 15 |
Sean M. McConachie, Sheila M. Wilhelm, Pramodini B. Kale-Pradhan. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology 2016; 9(2): 287 doi: 10.1586/17512433.2016.1129272
|
| 16 |
Jacqueline Farinha Shimizu, Caroline Sprengel Lima, Carina Machado Pereira, Cintia Bittar, Mariana Nogueira Batista, Ana Carolina Nazaré, Carlos Roberto Polaquini, Carsten Zothner, Mark Harris, Paula Rahal, Luis Octávio Regasini, Ana Carolina Gomes Jardim. Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-16336-y
|
| 17 |
Robert E Lanford, Christopher M Walker, Stanley M Lemon. The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis. ILAR Journal 2017; 58(2): 172 doi: 10.1093/ilar/ilx028
|
| 18 |
Yosuke Hirotsu, Tatsuo Kanda, Hiroshi Matsumura, Mitsuhiko Moriyama, Osamu Yokosuka, Masao Omata. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatology International 2015; 9(3): 424 doi: 10.1007/s12072-015-9624-2
|
| 19 |
K. V. Kalashnyk, O. V. Riabokon, O. V. Tsarova, Yu. Yu. Riabokon, H. V. Yalova. ЕФЕКТИВНІСТЬ РІЗНИХ СХЕМ ПРОТИВІРУСНОЇ ТЕРАПІЇ ХВОРИХ НА ХРОНІЧНИЙ ГЕПАТИТ С, ІНФІКОВАНИХ 1-м ГЕНОТИПОМ ВІРУСУ. Інфекційні хвороби 2019; (2): 15 doi: 10.11603/1681-2727.2019.2.10321
|
| 20 |
Celia Perales, Josep Quer, Josep Gregori, Juan Esteban, Esteban Domingo. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses 2015; 7(11): 5746 doi: 10.3390/v7112902
|
| 21 |
Javier Ampuero, K Rajender Reddy, Manuel Romero-Gomez. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World Journal of Gastroenterology 2016; 22(22): 5285-5292 doi: 10.3748/wjg.v22.i22.5285
|
| 22 |
Michael J. Sofia. New Drug Development for Known and Emerging Viruses. Methods and Principles in Medicinal Chemistry 2022; : 13 doi: 10.1002/9783527810697.ch2
|
| 23 |
Marawan Ahmed, Abhishek Pal, Michael Houghton, Khaled Barakat. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry. ACS Infectious Diseases 2016; 2(11): 872 doi: 10.1021/acsinfecdis.6b00113
|
| 24 |
Martha T. van der Beek, Eric C. J. Claas. Clinical Virology Manual. 2016; : 201 doi: 10.1128/9781555819156.ch16
|
| 25 |
Jun Itakura, Masayuki Kurosaki, Hitomi Takada, Natsuko Nakakuki, Syuya Matsuda, Kouichi Gondou, Yu Asano, Nobuhiro Hattori, Yoshie Itakura, Nobuharu Tamaki, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa, Kaoru Tsuchiya, Hiroyuki Nakanishi, Yuka Takahashi, Syinya Maekawa, Nobuyuki Enomoto, Namiki Izumi. Naturally occurring, resistance‐associated hepatitis C virus NS5A variants are linked to interleukin‐28B genotype and are sensitive to interferon‐based therapy. Hepatology Research 2015; 45(10) doi: 10.1111/hepr.12474
|
| 26 |
Cecilia Trucchi, Andrea Orsi, Cristiano Alicino, Laura Sticchi, Giancarlo Icardi, Filippo Ansaldi. State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. Journal of Immunology Research 2016; 2016: 1 doi: 10.1155/2016/1412840
|
| 27 |
Miguel Jiménez-Pérez, Rocío González-Grande, Pilar España Contreras, Isabel Pinazo Martínez, Jesús de la Cruz Lombardo, Raúl Olmedo Martín. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. World Journal of Gastroenterology 2016; 22(29): 6573-6581 doi: 10.3748/wjg.v22.i29.6573
|
| 28 |
Yuan-yuan Ma, Jian-rui Li, Zong-gen Peng, Jing-pu Zhang. IL28A protein homotetramer structure is required for autolysosomal degradation of HCV-NS5A in vitro. Cell Death & Disease 2020; 11(3) doi: 10.1038/s41419-020-2400-9
|
| 29 |
Emma Hathorn, Ahmed M Elsharkawy. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterology 2016; 3(1): e000112 doi: 10.1136/bmjgast-2016-000112
|
| 30 |
Mario Fernández-Ruiz, Natalia Polanco, Ana García-Santiago, Raquel Muñoz, Ana M. Hernández, Esther González, Verónica R. Mercado, Inmaculada Fernández, José María Aguado, Manuel Praga, Amado Andrés. Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study. Transplant International 2018; 31(8): 887 doi: 10.1111/tri.13118
|
| 31 |
Christoph Sarrazin. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of Hepatology 2016; 64(2): 486 doi: 10.1016/j.jhep.2015.09.011
|
| 32 |
Nicola Coppola, Carmine Minichini, Mario Starace, Caterina Sagnelli, Evangelista Sagnelli. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. Journal of Medical Virology 2016; 88(10): 1659 doi: 10.1002/jmv.24527
|
| 33 |
Chandana Papudesu, Shyamasundaran Kottilil, Shashwatee Bagchi. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatology International 2017; 11(2): 152 doi: 10.1007/s12072-016-9761-2
|
| 34 |
Tania M. Welzel, Neeru Bhardwaj, Charlotte Hedskog, Krishna Chodavarapu, Gregory Camus, John McNally, Diana Brainard, Michael D. Miller, Hongmei Mo, Evguenia Svarovskaia, Ira Jacobson, Stefan Zeuzem, Kosh Agarwal. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. Journal of Hepatology 2017; 67(2): 224 doi: 10.1016/j.jhep.2017.03.014
|
| 35 |
Fabián Aldunate, Natalia Echeverría, Daniela Chiodi, Pablo López, Adriana Sánchez-Cicerón, Alvaro Fajardo, Martín Soñora, Juan Cristina, Nelia Hernández, Pilar Moreno. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients. Disease Markers 2018; 2018: 1 doi: 10.1155/2018/2514901
|
| 36 |
Fernanda Malta, Karine Vieira Gaspareto, Gaspar Lisboa-Neto, Flair José Carrilho, Maria Cássia Mendes-Correa, João Renato Rebello Pinho. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. BMC Infectious Diseases 2017; 17(1) doi: 10.1186/s12879-017-2817-7
|
| 37 |
Saba Khaliq, Syed Raza. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. Medicina 2018; 54(5): 80 doi: 10.3390/medicina54050080
|
| 38 |
Pooneh Rahimi, Heidar Sharafi, Golnaz Bahramali, FaridehSadat SajadianFard, Nafiseh Sadat Asadi, Seyed Moayed Alavian, Vahid Iranpur Mobarakeh, Seyedeh Zahra Moravej. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. Frontiers in Microbiology 2021; 11 doi: 10.3389/fmicb.2020.617375
|
| 39 |
Palak K. Parikh, Nisha H. Parikh, Mahalakshmi B, Ketan M. Ranch, Sai H.S. Boddu, Jayachandra Babu R, Amit K. Tiwari. Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials. Arabian Journal of Chemistry 2023; 16(8): 105013 doi: 10.1016/j.arabjc.2023.105013
|
| 40 |
D. Banerjee, K. R. Reddy. Review article: safety and tolerability of direct‐acting anti‐viral agents in the new era of hepatitis C therapy. Alimentary Pharmacology & Therapeutics 2016; 43(6): 674 doi: 10.1111/apt.13514
|
| 41 |
Daniele Serranti, Giuseppe Indolfi, Massimo Resti. New treatments for chronic hepatitis C: An overview for paediatricians. World Journal of Gastroenterology 2014; 20(43): 15965-15974 doi: 10.3748/wjg.v20.i43.15965
|
| 42 |
Chun-Ming Hong, You-Yu Lin, Chun-Jen Liu, Ya-Yun Lai, Shiou-Hwei Yeh, Hung-Chih Yang, Jia-Horng Kao, Shih-Jer Hsu, Yi-Hsiang Huang, Sheng-Shun Yang, Hsing-Tao Kuo, Pin-Nan Cheng, Ming-Lung Yu, Pei-Jer Chen. Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan. Viruses 2021; 13(11): 2294 doi: 10.3390/v13112294
|
| 43 |
V. E. Ekushov, A. V. Totmenin, L. G. Gotfrid, M. R. Halikov, V.-V. V. Minikhanova, S. E. Skudarnov, T. S. Ostapova, N. M. Gashnikova. Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region. South of Russia: ecology, development 2024; 19(1): 47 doi: 10.18470/1992-1098-2024-1-4
|
| 44 |
Matthew L. Scherer, Chelsea Sammons, Brian Nelson, Scott M. Hammer, Elizabeth Verna. Clinical Virology. 2016; : 239 doi: 10.1128/9781555819439.ch13
|
| 45 |
Yan A. Ivanenkov, Vladimir A. Aladinskiy, Nikolay A. Bushkov, Andrey A. Ayginin, Alexander G. Majouga, Alexandre V. Ivachtchenko. Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015). Expert Opinion on Therapeutic Patents 2017; 27(4): 401 doi: 10.1080/13543776.2017.1272573
|
| 46 |
Rebecca Cope, Aaron Pickering, Thomas Glowa, Samantha Faulds, Peter Veldkamp, Ramakrishna Prasad. Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals. AIDS Patient Care and STDs 2015; 29(7): 379 doi: 10.1089/apc.2015.0004
|
| 47 |
Barbara Bartolini, Emanuela Giombini, Chiara Taibi, Raffaella Lionetti, Marzia Montalbano, Ubaldo Visco-Comandini, Gianpiero D’Offizi, Maria Rosaria Capobianchi, Fiona McPhee, Anna Rosa Garbuglia. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Viruses 2017; 9(8): 212 doi: 10.3390/v9080212
|
| 48 |
Yun Zhang, Christian Zmasek, Guangyu Sun, Christopher N. Larsen, Richard H. Scheuermann. Hepatitis C Virus Protocols. Methods in Molecular Biology 2019; 1911: 47 doi: 10.1007/978-1-4939-8976-8_3
|
| 49 |
Namiki Izumi. Efficacy of daclatasvir in hepatitis C virus. Expert Review of Anti-infective Therapy 2014; 12(9): 1025 doi: 10.1586/14787210.2014.942282
|
| 50 |
Valeria Cento, Stephane Chevaliez, Carlo Federico Perno. Resistance to direct-acting antiviral agents. Current Opinion in HIV and AIDS 2015; 10(5): 381 doi: 10.1097/COH.0000000000000177
|
| 51 |
Esteban Domingo, Carlos García-Crespo, María Eugenia Soria, Celia Perales. Viral Fitness and Evolution. Current Topics in Microbiology and Immunology 2023; 439: 197 doi: 10.1007/978-3-031-15640-3_6
|
| 52 |
Simona Ruta, Costin Cernescu. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World Journal of Gastroenterology 2015; 21(38): 10811-10823 doi: 10.3748/wjg.v21.i38.10811
|
| 53 |
Xia Jiang, Tatsuo Kanda, Shuang Wu, Shingo Nakamoto, Takaji Wakita, Hiroshi Shirasawa, Osamu Yokosuka, Ranjit Ray. Hepatitis C Virus Nonstructural Protein 5A Inhibits Thapsigargin-Induced Apoptosis. PLoS ONE 2014; 9(11): e113499 doi: 10.1371/journal.pone.0113499
|
| 54 |
Ahmed S Fayed, Maha A Hegazy, Ebraam B Kamel, Maya S Eissa. HPLC-UV and TLC-Densitometry Methods for Simultaneous Determination of Sofosbuvir and Daclatasvir: Application to Darvoni® Tablet. Journal of Chromatographic Science 2022; 60(6): 606 doi: 10.1093/chromsci/bmab100
|
| 55 |
Steven W. Johnson, Shelby R. Ammirati, Charles E. Hartis, Stephen F. Weber, Michael R. Morgan, Timothy A. Darnell, Adwait Silwal, Holly N. Schmidlin, David H. Priest. Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach. International Journal of Antimicrobial Agents 2017; 49(6): 778 doi: 10.1016/j.ijantimicag.2017.01.016
|
| 56 |
Claudia Palladino, Marta Sánchez-Carrillo, Irene Mate-Cano, Sonia Vázquez-Morón, Ma Ángeles Jimenez-Sousa, Mónica Gutiérrez-Rivas, Salvador Resino, Verónica Briz. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-02968-7
|
| 57 |
Tatsuo Kanda, Kazushige Nirei, Naoki Matsumoto, Teruhisa Higuchi, Hitomi Nakamura, Hiroaki Yamagami, Shunichi Matsuoka, Mitsuhiko Moriyama. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World Journal of Gastroenterology 2017; 23(46): 8120-8127 doi: 10.3748/wjg.v23.i46.8120
|
| 58 |
Hui-Chun Li, Chee-Hing Yang, Shih-Yen Lo. Hepatitis C Viral Replication Complex. Viruses 2021; 13(3): 520 doi: 10.3390/v13030520
|
| 59 |
Laura Riva, Sarah Goellner, Scott B. Biering, Chun-Teng Huang, Andrey N. Rubanov, Uta Haselmann, Colin M. Warnes, Paul D. De Jesus, Laura Martin-Sancho, Alexey V. Terskikh, Eva Harris, Anthony B. Pinkerton, Ralf Bartenschlager, Sumit K. Chanda, Susana López.
The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking
De Novo
Formation of the Membranous Replication Compartment
. Journal of Virology 2021; 95(22) doi: 10.1128/JVI.00996-21
|
| 60 |
Julie Sheldon, Nathan M. Beach, Elena Moreno, Isabel Gallego, David Piñeiro, Encarnación Martínez-Salas, Josep Gregori, Josep Quer, Juan Ignacio Esteban, Charles M. Rice, Esteban Domingo, Celia Perales, M. S. Diamond. Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus. Journal of Virology 2014; 88(20): 12098 doi: 10.1128/JVI.01860-14
|
| 61 |
Mohammad Saeid Rezaee-Zavareh, Khashayar Hesamizadeh, Heidar Sharafi, Seyed Moayed Alavian. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis. Hepatitis Monthly 2017; 17(6) doi: 10.5812/hepatmon.12324
|
| 62 |
Nimisha Chaturvedi, Evguenia S Svarovskaia, Hongmei Mo, Anu O Osinusi, Diana M Brainard, G Mani Subramanian, John G McHutchison, Stefan Zeuzem, Jacques Fellay. Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. eLife 2019; 8 doi: 10.7554/eLife.42542
|
| 63 |
Jung Hwan Yu, Jung Il Lee, Kwan Sik Lee, Ja Kyung Kim. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C. Virology Journal 2017; 14(1) doi: 10.1186/s12985-017-0826-1
|
| 64 |
Carlos García-Crespo, Lucía Vázquez-Sirvent, Pilar Somovilla, María Eugenia Soria, Isabel Gallego, Ana Isabel de Ávila, Brenda Martínez-González, Antoni Durán-Pastor, Esteban Domingo, Celia Perales. Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.960676
|
| 65 |
John T. Randolph, Charles A. Flentge, Pamela Donner, Todd W. Rockway, Sachin V. Patel, Lissa Nelson, Douglas K. Hutchinson, Rubina Mondal, Neeta Mistry, Thomas Reisch, Tatyana Dekhtyar, Preethi Krishnan, Tami Pilot-Matias, Deanne F. Stolarik, David W.A. Beno, Rolf Wagner, Clarence Maring, Warren M. Kati. Discovery of fluorobenzimidazole HCV NS5A inhibitors. Bioorganic & Medicinal Chemistry Letters 2016; 26(22): 5462 doi: 10.1016/j.bmcl.2016.10.030
|
| 66 |
Fred Poordad, Charles S. Landis, Armen Asatryan, Daniel F. Jackson, Teresa I. Ng, Bo Fu, Chih‐Wei Lin, Betty Yao, Jens Kort. High antiviral activity of NS5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver International 2016; 36(8): 1125 doi: 10.1111/liv.13067
|
| 67 |
Andri Frediansyah, Fajar Sofyantoro, Saad Alhumaid, Abbas Al Mutair, Hawra Albayat, Hayyan I. Altaweil, Hani M. Al-Afghani, Abdullah A. AlRamadhan, Mariam R. AlGhazal, Safaa A. Turkistani, Abdulmonem A. Abuzaid, Ali A. Rabaan. Microbial Natural Products with Antiviral Activities, Including Anti-SARS-CoV-2: A Review. Molecules 2022; 27(13): 4305 doi: 10.3390/molecules27134305
|
| 68 |
Tomoko Tadokoro, Asahiro Morishita, Koji Fujita, Kyoko Oura, Teppei Sakamoto, Takako Nomura, Joji Tani, Hirohito Yoneyama, Tsutomu Masaki. Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. Internal Medicine 2018; 57(8): 1101 doi: 10.2169/internalmedicine.9744-17
|
| 69 |
Daisy Yan, Bingfang Yan. Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. Fundamental & Clinical Pharmacology 2023; 37(4): 726 doi: 10.1111/fcp.12889
|
| 70 |
Austin Chan, Keyur Patel, Susanna Naggie. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs 2017; 77(2): 131 doi: 10.1007/s40265-016-0685-x
|
| 71 |
Lei Dai, Yushen Du, Hangfei Qi, Christian D. Huber, Dongdong Chen, Tian-Hao Zhang, Nicholas C. Wu, Ergang Wang, James O. Lloyd-Smith, Ren Sun, Tiffany A. Reese. Quantifying the Evolutionary Constraints and Potential of Hepatitis C Virus NS5A Protein. mSystems 2021; 6(2) doi: 10.1128/mSystems.01111-20
|
| 72 |
Bianca Heinrich, John P. Bilello. Antimicrobial Drug Resistance. 2017; : 579 doi: 10.1007/978-3-319-46718-4_39
|
| 73 |
Eugene Choi, Dong-Gyun Han, Jeong-Eun Park, Ha-Yeon Lee, Jin-Wook Yoo, Yunjin Jung, Im-Sook Song, In-Soo Yoon. A simple and sensitive HPLC-FL method for bioanalysis of velpatasvir, a novel hepatitis C virus NS5A inhibitor, in rat plasma: Investigation of factors determining its oral bioavailability. Journal of Chromatography B 2022; 1208: 123399 doi: 10.1016/j.jchromb.2022.123399
|
| 74 |
O. Tronina, K. Ślubowska, N. Mikołajczyk-Korniak, E. Komuda-Leszek, R. Wieczorek-Godlewska, B. Łągiewska, M. Pacholczyk, W. Lisik, M. Kosieradzki, M. Durlik. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Transplantation Proceedings 2017; 49(6): 1409 doi: 10.1016/j.transproceed.2017.01.077
|
| 75 |
Tayebeh Hashempour, Behzad Dehghani, Zahra Mousavi, Tahereh Akbari, Zahra Hasanshahi, Javad Moayedi, Maryam Yahaghi, Mohammad Ali Davarpanah. Association of Mutations in the NS5A-PKRBD Region and IFNL4 Genotypes with Hepatitis C Interferon Responsiveness and its Functional and Structural Analysis. Current Proteomics 2021; 18(1): 38 doi: 10.2174/1570164617666200107091124
|
| 76 |
Celia Perales, Ana M. Ortega-Prieto, Nathan M. Beach, Julie Sheldon, Luis Menéndez-Arias, Esteban Domingo. Handbook of Antimicrobial Resistance. 2014; : 1 doi: 10.1007/978-1-4939-0667-3_1-1
|
| 77 |
Antonio Craxì, Carlo Federico Perno, Mauro Viganò, Francesca Ceccherini-Silberstein, Salvatore Petta, Alessio Aghemo, Alfredo Alberti, Pietro Andreone, Massimo Andreoni, Stefano Bonora, Maurizia Rossana Brunetto, Savino Bruno, Nicola Caporaso, Antonio Chirianni, Alessia Ciancio, Elisabetta Degasperi, Giovanni Di Perri, Stefano Fagiuoli, Carlo Ferrari, Giovanni Battista Gaeta, Adriano Pellicelli, Massimo Puoti, Giovanni Raimondo, Gloria Taliani, Erica Villa, Anna Linda Zignego. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016; 48(9): 995 doi: 10.1016/j.dld.2016.06.004
|
| 78 |
María Eugenia Soria, Carlos García-Crespo, Brenda Martínez-González, Lucía Vázquez-Sirvent, Rebeca Lobo-Vega, Ana Isabel de Ávila, Isabel Gallego, Qian Chen, Damir García-Cehic, Meritxell Llorens-Revull, Carlos Briones, Jordi Gómez, Cristina Ferrer-Orta, Nuria Verdaguer, Josep Gregori, Francisco Rodríguez-Frías, María Buti, Juan Ignacio Esteban, Esteban Domingo, Josep Quer, Celia Perales, Yi-Wei Tang. Amino Acid Substitutions Associated with Treatment Failure for Hepatitis C Virus Infection. Journal of Clinical Microbiology 2020; 58(12) doi: 10.1128/JCM.01985-20
|
| 79 |
Ayman Geddawy, Yasmine F. Ibrahim, Nabil M. Elbahie, Mohammad A. Ibrahim. Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction. Journal of Translational Internal Medicine 2017; 5(1): 8 doi: 10.1515/jtim-2017-0007
|
| 80 |
Min Gao, Donald R O’Boyle, Susan Roberts. HCV NS5A replication complex inhibitors. Current Opinion in Pharmacology 2016; 30: 151 doi: 10.1016/j.coph.2016.07.014
|
| 81 |
Carlos García-Crespo, Isabel Gallego, María Eugenia Soria, Ana Isabel de Ávila, Brenda Martínez-González, Lucía Vázquez-Sirvent, Rebeca Lobo-Vega, Elena Moreno, Jordi Gómez, Carlos Briones, Josep Gregori, Josep Quer, Esteban Domingo, Celia Perales. Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus. Viruses 2021; 13(4): 616 doi: 10.3390/v13040616
|
| 82 |
Jameleddine Aissa Larousse, Pascale Trimoulet, Patricia Recordon Pinson, Brigitte Tauzin, Mohamed Mssadak Azzouz, Nabyl Ben Mami, Imed Cheikh, Henda Triki, Hervé Fleury. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia. Virology Journal 2015; 12(1) doi: 10.1186/s12985-015-0318-0
|
| 83 |
Rafael Alves da Silva, Jardelina de Souza Todão, Fernando Luiz Kamitani, Antonio Eduardo Benedito Silva, Roberto José de Carvalho‐Filho, Maria Lucia Cardoso Gomes Ferraz, Isabel Maria Vicente Guedes de Carvalho. Molecular characterization of hepatitis C virus in end‐stage renal disease patients under hemodialysis. Journal of Medical Virology 2018; 90(3): 537 doi: 10.1002/jmv.24976
|
| 84 |
Robert J. Fontana, Robert S. Brown, Ana Moreno‐Zamora, Martin Prieto, Shobha Joshi, Maria‐Carlota Londoño, Kerstin Herzer, Kristina R. Chacko, Rudolf E. Stauber, Viola Knop, Syed‐Mohammed Jafri, Lluís Castells, Peter Ferenci, Carlo Torti, Christine M. Durand, Laura Loiacono, Raffaella Lionetti, Ranjeeta Bahirwani, Ola Weiland, Abdullah Mubarak, Ahmed M. ElSharkawy, Bernhard Stadler, Marzia Montalbano, Christoph Berg, Adriano M. Pellicelli, Stephan Stenmark, Francis Vekeman, Raluca Ionescu‐Ittu, Bruno Emond, K. Rajender Reddy. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transplantation 2016; 22(4): 446 doi: 10.1002/lt.24416
|
| 85 |
Guglielmo Borgia, Alberto Enrico Maraolo, Salvatore Nappa, Ivan Gentile, Antonio Riccardo Buonomo. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opinion on Investigational Drugs 2018; 27(3): 243 doi: 10.1080/13543784.2018.1420780
|
| 86 |
Olga M. Klibanov, Stormi E. Gale, Barbara Santevecchi. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Tablets for Hepatitis C Virus Genotype 1 Infection. Annals of Pharmacotherapy 2015; 49(5): 566 doi: 10.1177/1060028015570729
|
| 87 |
Vanessa Costilla, Neha Mathur, Julio A. Gutierrez. Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. Clinics in Liver Disease 2015; 19(4): 641 doi: 10.1016/j.cld.2015.06.005
|
| 88 |
Phil McEwan, Thomas Ward, Samantha Webster, Yong Yuan, Anupama Kalsekar, Isao Kamae, Masahiro Kobayashi, Ann Tang, Hiromitsu Kumada. Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatology Research 2016; 46(5): 423 doi: 10.1111/hepr.12570
|
| 89 |
Duozhi Chen, Jieyun Cai, Junlin Yin, Jiandong Jiang, Chenxu Jing, Yanping Zhu, Junjun Cheng, Yingtong Di, Yu Zhang, Mingming Cao, Shunlin Li, Zonggen Peng, Xiaojiang Hao. Lycorine-derived phenanthridine downregulators of host Hsc70 as potential hepatitis C virus inhibitors. Future Medicinal Chemistry 2015; 7(5): 561 doi: 10.4155/fmc.15.14
|
| 90 |
Stefano Gitto, Nesrine Gamal, Pietro Andreone. NS5A inhibitors for the treatment of hepatitis C infection. Journal of Viral Hepatitis 2017; 24(3): 180 doi: 10.1111/jvh.12657
|
| 91 |
Jun Ito, Goki Suda, Yoshiya Yamamoto, Atsushi Nagasaka, Ken Furuya, Kenichi Kumagai, Hideaki Kikuchi, Takuto Miyagishima, Tomoe Kobayashi, Megumi Kimura, Kazushi Yamasaki, Machiko Umemura, Takaaki Izumi, Seiji Tsunematsu, Fumiyuki Sato, Yoko Tsukuda, Katsumi Terashita, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto. Prevalence and characteristics of naturally occurring sofosbuvir resistance‐associated variants in patients with hepatitis C virus genotype 1b infection. Hepatology Research 2016; 46(13): 1294 doi: 10.1111/hepr.12685
|
| 92 |
Zhenqiu Liu, Xianhua Mao, Jiaqi Wu, Kangkang Yu, Qin Yang, Chen Suo, Ming Lu, Li Jin, Tiejun Zhang, Xingdong Chen. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology 2021; 19(9): 1906 doi: 10.1016/j.cgh.2019.10.046
|
| 93 |
Aqsa Ikram, Ayesha Obaid, Faryal Mehwish Awan, Rumeza Hanif, Anam Naz, Rehan Zafar Paracha, Amjad Ali, Hussnain Ahmed Janjua. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine. Antiviral Research 2017; 137: 112 doi: 10.1016/j.antiviral.2016.10.013
|
| 94 |
Ruben Brandão, Rute Marcelino, Fátima Gonçalves, Isabel Diogo, Ana Carvalho, Joaquim Cabanas, Inês Costa, Pedro Brogueira, Fernando Ventura, Ana Miranda, Kamal Mansinho, Perpétua Gomes. Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. Viruses 2018; 10(5): 223 doi: 10.3390/v10050223
|
| 95 |
A. Ferreira-Gonzalez. Diagnostic Molecular Pathology. 2017; : 485 doi: 10.1016/B978-0-12-800886-7.00038-8
|
| 96 |
Vinay Sundaram, Kris V. Kowdley. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 2016; 10(1): 13 doi: 10.1586/17474124.2016.1116937
|
| 97 |
Tatsuo Kanda, Shin Yasui, Masato Nakamura, Eiichiro Suzuki, Makoto Arai, Yoshihiko Ooka, Sadahisa Ogasawara, Tetsuhiro Chiba, Tomoko Saito, Yuki Haga, Koji Takahashi, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Akinobu Tawada, Hitoshi Maruyama, Fumio Imazeki, Naoya Kato, Osamu Yokosuka. Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. International Journal of Molecular Sciences 2017; 18(5): 906 doi: 10.3390/ijms18050906
|
| 98 |
Daniel M. Forton. How much of a problem is resistance in treating hepatitis C?. Current Opinion in Infectious Diseases 2016; 29(6): 625 doi: 10.1097/QCO.0000000000000319
|
| 99 |
Sakura Akamatsu, C. Nelson Hayes, Hidenori Ochi, Takuro Uchida, Hiromi Kan, Eisuke Murakami, Hiromi Abe, Masataka Tsuge, Daiki Miki, Rie Akiyama, Nobuhiko Hiraga, Michio Imamura, Hiroshi Aikata, Tomokazu Kawaoka, Yoshiiku Kawakami, Kazuaki Chayama. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. Journal of Hepatology 2015; 63(3): 554 doi: 10.1016/j.jhep.2015.03.033
|
| 100 |
Szu-Jen Wang, Chung-Feng Huang, Ming-Lung Yu. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Review of Anti-infective Therapy 2021; 19(9): 1071 doi: 10.1080/14787210.2021.1874351
|
| 101 |
Natalia Echeverría, Pilar Moreno, Juan Cristina. Human Virology in Latin America. 2017; : 333 doi: 10.1007/978-3-319-54567-7_17
|
| 102 |
Mohd Suhail, Sayed Sartaj Sohrab, Abid Qureshi, Mohd Tarique, Hany Abdel-Hafiz, Khalid Al-Ghamdi, Ishtiaq Qadri. Association of HCV mutated proteins and host SNPs in the development of hepatocellular carcinoma. Infection, Genetics and Evolution 2018; 60: 160 doi: 10.1016/j.meegid.2018.02.034
|